Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Crohn's disease (CD) for at least 90 days.~2. Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450.~3. Subject inadequately responded to or experienced intolerance to previous treatment with immunomodulators (e.g. azathioprine, 6-mercaptopurine, or methotrexate) and/or anti-TNF agent (e.g., infliximab, adalimumab, or certolizumab pegol).~Exclusion Criteria:~1. Subjects with ulcerative colitis (UC), collagenous colitis or indeterminate colitis.~2. Subject who has had surgical bowel resections in the past 6 months or is planning resection.~3. Subjects with an ostomy or ileoanal pouch.~4. Subject with symptomatic bowel stricture or abdominal or peri-anal abcess.~5. Subject who has short bowel syndrome.~6. Subject with recurring infections or active Tuberculosis (TB).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Induction Period ABT-494 Twice Daily Medium/High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
- Extension Phase ABT-494 High Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 High Dose orally dosed twice a day
- Induction Period Placebo (Type: PLACEBO_COMPARATOR): Induction Period Placebo orally dosed twice a day
- Induction Period ABT-494 Low Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Low Dose orally dosed twice a day
- Induction Period ABT-494 Once Daily Medium/High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
- Extension Phase ABT-494 Low Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 Low Dose orally dosed twice a day
- Induction Period ABT-494 High Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 High Dose orally dosed twice a day
- Induction Period ABT-494 Low/Medium Dose (Type: ACTIVE_COMPARATOR): Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
- Extension Phase ABT-494 Medium Dose (Type: ACTIVE_COMPARATOR): Extension Phase ABT-494 Medium Dose orally dosed twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).